Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| rac1 GTP-Binding Protein | 9 | 2026 | 50 | 1.520 |
Why?
|
| Carbazoles | 7 | 2026 | 49 | 1.490 |
Why?
|
| Pyrimidines | 7 | 2026 | 139 | 1.210 |
Why?
|
| Drug Design | 4 | 2026 | 186 | 1.080 |
Why?
|
| rac GTP-Binding Proteins | 4 | 2022 | 26 | 0.800 |
Why?
|
| Aminoquinolines | 3 | 2013 | 17 | 0.460 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 1019 | 0.430 |
Why?
|
| Enzyme Inhibitors | 2 | 2013 | 458 | 0.420 |
Why?
|
| Proto-Oncogene Proteins c-vav | 3 | 2025 | 8 | 0.380 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2023 | 51 | 0.360 |
Why?
|
| Warfarin | 2 | 2023 | 67 | 0.350 |
Why?
|
| Drug Industry | 1 | 2009 | 18 | 0.310 |
Why?
|
| cdc42 GTP-Binding Protein | 2 | 2021 | 25 | 0.310 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 1723 | 0.250 |
Why?
|
| Crystallization | 2 | 2025 | 88 | 0.230 |
Why?
|
| Nitrofurans | 1 | 2025 | 3 | 0.230 |
Why?
|
| Antimalarials | 1 | 2026 | 64 | 0.230 |
Why?
|
| Insulin-Secreting Cells | 2 | 2015 | 28 | 0.230 |
Why?
|
| Nitrates | 1 | 2025 | 63 | 0.220 |
Why?
|
| Plasmodium falciparum | 1 | 2026 | 144 | 0.220 |
Why?
|
| Biomedical Research | 1 | 2009 | 502 | 0.210 |
Why?
|
| Cell Movement | 4 | 2025 | 655 | 0.210 |
Why?
|
| p21-Activated Kinases | 2 | 2013 | 21 | 0.200 |
Why?
|
| Glucose | 2 | 2015 | 244 | 0.200 |
Why?
|
| Cell Line, Tumor | 6 | 2025 | 2676 | 0.190 |
Why?
|
| Cell Proliferation | 5 | 2025 | 1455 | 0.190 |
Why?
|
| GTP-Binding Proteins | 1 | 2022 | 59 | 0.190 |
Why?
|
| Structure-Activity Relationship | 2 | 2026 | 506 | 0.170 |
Why?
|
| Humans | 14 | 2026 | 43102 | 0.140 |
Why?
|
| Binding Sites | 2 | 2018 | 671 | 0.140 |
Why?
|
| Protein Structure, Tertiary | 1 | 2018 | 423 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 139 | 0.120 |
Why?
|
| Prostatic Neoplasms | 1 | 2025 | 1092 | 0.120 |
Why?
|
| Animals | 9 | 2023 | 16992 | 0.110 |
Why?
|
| Technology, Pharmaceutical | 2 | 2025 | 35 | 0.110 |
Why?
|
| Chemistry, Pharmaceutical | 2 | 2025 | 97 | 0.110 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 105 | 0.110 |
Why?
|
| Drug Compounding | 2 | 2025 | 93 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2017 | 237 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 14 | 0.100 |
Why?
|
| Mice | 6 | 2023 | 6644 | 0.100 |
Why?
|
| Cell Survival | 4 | 2023 | 945 | 0.100 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 224 | 0.100 |
Why?
|
| Molecular Structure | 2 | 2026 | 570 | 0.100 |
Why?
|
| Insulin | 1 | 2015 | 258 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2013 | 38 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 465 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 241 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2023 | 122 | 0.090 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2010 | 157 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 508 | 0.080 |
Why?
|
| Genotype | 2 | 2023 | 800 | 0.080 |
Why?
|
| Congresses as Topic | 1 | 2009 | 50 | 0.080 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2026 | 15 | 0.060 |
Why?
|
| Tablets | 1 | 2025 | 14 | 0.060 |
Why?
|
| Capsules | 1 | 2025 | 28 | 0.060 |
Why?
|
| Furaldehyde | 1 | 2025 | 4 | 0.060 |
Why?
|
| Solvents | 1 | 2025 | 113 | 0.060 |
Why?
|
| Polyethylene Glycols | 1 | 2025 | 108 | 0.060 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2023 | 15 | 0.050 |
Why?
|
| Pharmaceutical Preparations | 1 | 2024 | 94 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2015 | 462 | 0.050 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2022 | 34 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2026 | 1124 | 0.050 |
Why?
|
| Cell Division | 1 | 2022 | 311 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2023 | 411 | 0.050 |
Why?
|
| Phase Transition | 1 | 2021 | 8 | 0.040 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2021 | 35 | 0.040 |
Why?
|
| X-Ray Diffraction | 1 | 2021 | 66 | 0.040 |
Why?
|
| Cell Line | 2 | 2015 | 1410 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2021 | 158 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2021 | 155 | 0.040 |
Why?
|
| Crystallography, X-Ray | 1 | 2021 | 280 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2015 | 1766 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 968 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2017 | 2157 | 0.030 |
Why?
|
| Female | 4 | 2021 | 24698 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 1596 | 0.030 |
Why?
|
| Guanosine Diphosphate | 1 | 2015 | 10 | 0.030 |
Why?
|
| Male | 3 | 2025 | 23409 | 0.030 |
Why?
|
| Protein Prenylation | 1 | 2015 | 12 | 0.030 |
Why?
|
| Guanosine Triphosphate | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cytoskeleton | 1 | 2015 | 114 | 0.030 |
Why?
|
| Actins | 1 | 2015 | 164 | 0.030 |
Why?
|
| Mastocytosis | 1 | 2013 | 3 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 317 | 0.030 |
Why?
|
| Mice, Inbred C3H | 1 | 2013 | 80 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2015 | 408 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 611 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 436 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 91 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2012 | 28 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2015 | 532 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 347 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 1081 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2012 | 296 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2013 | 1869 | 0.020 |
Why?
|
| Rats | 1 | 2015 | 3735 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1568 | 0.020 |
Why?
|